Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 864 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
16 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Amherst, New York
Completed Not applicable Interventional Results available

Virtual Reality to Improve Social Perspective Taking

NCT03927612
Conditions
Conduct Disorder, Child, Adolescent, Attention Deficit and Disruptive Behavior Disorders, Child Behavior Disorders, Virtual Reality, Social Perception, Magnetic Resonance Imaging
Interventions
Virtual reality perspective taking training, Virtual reality control perspective
Device
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Conditions
Autism, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
ADHD
Interventions
Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex
Device
Lead sponsor
Bradley Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
East Providence, Rhode Island
Conditions
ADHD, Autism
Interventions
Observation
Other
Lead sponsor
MaxisHealth
Industry
Eligibility
4 Years to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Digital Treatment
Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Garden Grove, California • Lauderhill, Florida + 11 more
Conditions
ADHD
Interventions
Brainsonix Pulsar 1002
Device
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Santa Monica, California
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
EMS 7500 Digital Muscle Stimulator
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
ADHD
Interventions
Focalin XR
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluating Treatment of ADHD in Children With Down Syndrome

NCT04219280
Conditions
Down Syndrome, ADHD
Interventions
Quillivant XR, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
4
States / cities
Sacramento, California • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Conditions
Attention Deficit Hyperactivity Disorder, Asthma, Autism Spectrum Disorder, Depression, Epilepsy
Interventions
TriVox for clinical care
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
946 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Adult Attention-Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester Hills, Michigan
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Interventions
CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 12 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
23
States / cities
Little Rock, Arkansas • Boulder, Colorado • Bradenton, Florida + 19 more
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Conditions
Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder
Interventions
Adderall-XR, Matched placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Conditions
Major Depressive Disorder, Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina